APA (7th ed.) Citation

TG, M., JWM, M., WJC, P. d. S., NS, V., CM, B., S, v. H., . . . A, H. (2024). Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient. Cancers, 16(4), . https://doi.org/10.3390/cancers16040741

Chicago Style (17th ed.) Citation

TG, Meijer, et al. "Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient." Cancers 16, no. 4 (2024). https://doi.org/10.3390/cancers16040741.

MLA (9th ed.) Citation

TG, Meijer, et al. "Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient." Cancers, vol. 16, no. 4, 2024, https://doi.org/10.3390/cancers16040741.